Steven A. Shallcross - 02 Feb 2023 Form 4 Insider Report for Theriva Biologics, Inc. (TOVX)

Role: CEO and CFO, Director
Signature: /s/ Steven A. Shallcross
Issuer symbol: TOVX
Transactions as of: 02 Feb 2023
Net transactions value: +$23,512
Form type: 4
Filing time: 03 Feb 2023, 05:02:07 UTC
Previous filing: 26 Jan 2023
Next filing: 13 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TOVX	Common Stock	Purchase	$23,512	+25,000	+16%	$0.9405	185,000	02 Feb 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.9349 through $0.9499, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Content

The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.9349 through $0.9499, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.